Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THREE-GLEES: L-TC with Chemoradiation in Newly Diagnosed Glioblastoma
NCT06477939Phase 3Not yet recruiting
- Sponsor
- Institut de cancérologie Strasbourg Europe
- Start
- Jan 2025
- Primary completion
- Dec 2032
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of trans sodium crocetinate in glioblastoma (GBM), sponsored by Institut de cancérologie Strasbourg Europe. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
trans sodium crocetinate
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06477939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06477939.